Effects of L‑carnitine supplementation on respiratory distress syndrome development and prognosis in premature infants: A single blind randomized controlled trial

Ozturk,Mehmet Adnan; Kardas,Zehra; Kardas,Fati̇h; Gunes,Tamer; Kurtoglu,Seli̇m

doi:10.3892/etm.2015.2964

Effects of L‑carnitine supplementation on respiratory distress syndrome development and prognosis in premature infants: A single blind randomized controlled trial

Authors:
- Mehmet Adnan Ozturk
- Zehra Kardas
- Fati̇h Kardas
- Tamer Gunes
- Seli̇m Kurtoglu
View Affiliations

Affiliations: Department of Pediatrics, Division of Neonatology, Erciyes University, School of Medicine, Kayseri 38039, Turkey, Department of Pediatrics, State Educational and Research Hospital of The Government, Kayseri 38039, Turkey, Department of Pediatrics, Division of Pediatric Nutrition and Metabolism, Erciyes University, School of Medicine, Kayseri 38039, Turkey
Published online on: December 29, 2015 https://doi.org/10.3892/etm.2015.2964
Pages: 1123-1127

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the efficacy of L‑carnitine therapy on the occurrence and prognosis of respiratory distress syndrome (RDS). A single blind, randomized controlled trial study was conducted on 130 infants with gestational ages of 28‑36 weeks. Infants were assigned to experimental groups (groups 1 and 2) and control groups (groups 3 and 4). Groups 1 and 3 consisted of infants with RDS, and groups 2 and 4 groups were composed of infants without RDS. The experimental groups were treated with carnitine. No statistically significant differences in serum carnitine levels were detected between the study and the control groups on day 1 of treatment (P=0.06). However, on day 7 of treatment, serum carnitine levels in the experimental groups were significantly increased (P=0.02), as compared with the control groups. The surfactant requirement value, which is how many rounds of surfactant therapy were required, was 1.56±0.97 in group 1, and 2.12±0.99 in group 3 (P<0.001). The mean duration of mechanical ventilation required was 3.04±3.60 days in group 1, and 4.73±5.63 days in group 3 (P<0.001). The present results indicate that carnitine supplementation in premature infants with RDS may help to increase carnitine levels, thus decreasing the duration of mechanical ventilation and surfactant requirement.

View Figures

View References

1	Hislop AA: Fetal and postnatal anatomical lung development. Neonatal Respiratory Disorders. Greenough A and Milner AD: (2nd). (London). Arnold Press. 247–251. 2003.
2	Ozturk MA, Gunes T, Koklu E and Erciyes A: Free carnitine levels in respiratory distress syndrome during the first week of life. Am J Perinatol. 23:445–459. 2006. View Article : Google Scholar : PubMed/NCBI
3	Korkmaz A, Tekinalp G, Coskun T, Yigit S and Yurdakok M: Plasma carnitine levels in preterm infants with respiratory distress syndrome. Pediatr Int. 47:49–52. 2005. View Article : Google Scholar : PubMed/NCBI
4	Harmeyer J: The physiological role of L-carnitine. Lohninger Information. 27:1–8. 2002.
5	Czeszyńska MB: Evaluation of fetal lung maturation in rabbits after giving carnitine and carnitine with betamethasone to pregnant rabbits. Ann Acad Med Stetin. 39:185–205. 1993.(In Polish). PubMed/NCBI
6	Salzer H, Husslein P, Lohninger A, Binstorfer E, Langer M, Schönbauer M, Wagner G, Simbruner G and Popow C: 1st report: Alternatives to cortisone therapy, 1st clinical experiences with a carnitine-betamethasone combination for the stimulation of the fetal lung maturity. Wien Klin Wochenschr. 95:724–728. 1983.(In German). PubMed/NCBI
7	Whitfield J, Smith T, Sollohub H, Sweetman L and Roe CR: Clinical effects of L-carnitine supplementation on apnea and growth in very low birth weight infants. Pediatrics. 111:477–482. 2003. View Article : Google Scholar : PubMed/NCBI
8	Kumar M, Kabra N and Paes B: Role of carnitine supplementation in apnea of prematurity: A systematic review. J Perinatol. 24:158–163. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kurz C, Arbeiter K, Obermair A, Salzer H, Salzer HR and Lohninger A: L-carnitine-betamethasone combination therapy versus betamethasone therapy alone in prevention of respiratory distress syndrome. Z Geburtshilfe Perinatol. 197:215–219. 1993.(In German). PubMed/NCBI
10	Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL and Lipp R: New Ballard Score, expanded to include extremely premature infants. J Pediatr. 119:417–23. 1991. View Article : Google Scholar : PubMed/NCBI
11	Jackson JC: Respiratory distress in the preterm infant. Avery's Diseases of the Newborn. Gleason CA and Devaskar US: (9th). (Philadelphia, PA). Elsevier Saunders. 633–646. 2012. View Article : Google Scholar
12	Jobe AH and Bancalar E: Hormoncuklardan dysplasia. Am J Respir Crit Care Med. 163:1723–1729. 2001. View Article : Google Scholar : PubMed/NCBI
13	Carlo WA: The newborn infant. Nelson Textbook of Pediatrics. Kliegman RM, Stanton BF, St. Geme JF III, Schor NF and Behrman RE: (19th). (Philadelphia, PA). Elsevier Saunders Press. 561–569. 2011.
14	Schulz KF, Altman DG and Moher D: CONSORT Group: CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMC Med. 8:182010. View Article : Google Scholar : PubMed/NCBI
15	Bancalari E and Claure N: Principles of respiratory monitoring and therapy. Avery's dıseases of the newborn. Gleason CA and Devaskar SU: (9th). (Philadelphia, PA). Elseiver Saunders Press. 612–632. 2012. View Article : Google Scholar
16	Douma C, Dawodu T and Patnode R: Appendix A: Common NICU medication guidelines. Manuel of Neonatal Care. Cloherty JH, Eichenwald EC and Stark AR: (6th). (Philadelphia, PA). Lippincott Williams & Wilkins. 675–715. 2008.
17	Eichenwald EC: Mechanical ventilation. Manuel of Neonatal Care. Cloherty JP, Eichenwald EC and Stark AR: (6th). (Philadelphia, PA). Lippincott Williams & Wilkins. 331–343. 2008.
18	British Columbia Reproductive Care Program: Newborn Guideline 6: Surfactant replacement therapy in neonates. British Columbia Reproductive Care Program (British Columbia, Canada). 2003.
19	Lohninger A, Krieglsteiner HP, Hajos F, Stangl H and Marz R: Effects of prenatal treatment with betamethasone, L-carnitine, or betamethasone-L-carnitine combinations on the phosphatidylcholine content and composition of the foetal and maternal rat lung. Eur J Clin Chem Clin Biochem. 34:387–391. 1996.PubMed/NCBI
20	Crill CM, Storm MC, Christensen ML, Hankins CT, Jenkins Bruce M and Helms RA: Carnitine supplementation in premature neonates: Effect on plasma and red blood cell total carnitine concentrations, nutrition parameters and morbidity. Clin Nutr. 25:886–896. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lohninger A, Krieglsteiner HP, Salzer H, Erhardt W, Eppl W and Kaiser E: Studies on the effects of L-thyroxine, L-carnitine and an L-thyroxine-L-carnitine combination on dipalmitoyl phosphatidylcholine content and on phosphatidylcholine species composition in fetal rat lungs. Pediatr Res. 20:1280–1283. 1986. View Article : Google Scholar : PubMed/NCBI
22	Goñi FM, Requero MA and Alonso A: Palmitoylcarnitine, a surface-active metabolite. FEBS Lett. 390:1–5. 1996. View Article : Google Scholar : PubMed/NCBI
23	Arenas J, Huertas R, Campos Y, Díaz AE, Villalón JM and Vilas E: Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett. 341:91–93. 1994. View Article : Google Scholar : PubMed/NCBI
24	Novak M: Carnitine in perinatal metabolism of lipids. L-Carnitine and its Role in Medicine: From Function to Therapy. Ferrari R, Di Mauro S and Sherwood G: (2nd). (London and New York). Academic Press. 104–112. 1992.
25	Hiatt WR, Regensteiner JG, Wolfel EE, Ruff L and Brass EP: Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. J Clin Invest. 84:1167–1173. 1989. View Article : Google Scholar : PubMed/NCBI
26	Meyburg J, Schulze A, Kohlmueller D, Pöschl J, Linderkamp O, Hoffmann GF and Mayatepek E: Acylcarnitine profiles of preterm infants over the first four weeks of life. Pediatric Res. 52:720–723. 2002. View Article : Google Scholar
27	Giannocopoulou C, Evangeliou A, Matalliotakis I, Relakis K, Sbirakis N, Hatzidaki E and Koumandakis E: Effect of gestation age and birth weight in the concentration of carnitine in the umbilical plasma. Clin Exp Obstet Gynecol. 25:42–45. 1998.PubMed/NCBI
28	Zaharia G, Ion DA, Schmidt N, Popa M, Kudor-Szabadi I and Zaharia T: Prophylactic versus therapeutic CPAP in preterm newborns of 28–32 gestational weeks. Pneumonologia. 57:34–37. 2008.(In Romanian).